CAJ | 학술논문

目的本研究旨在探讨SDZ PSC833和维拉帕米(verapamil,VER)对丝裂霉素(MMC)体外增效作用。方法以人宫颈癌Hela细胞和耐药亚系Hela／MMC细胞为材料，观察了SDZ PSC833和VER对MMC体外增效作用。结果无毒剂量的SDZ PSC833和VER(1～3mg/L)可显著增加MMC的细胞毒作用且可基本克服Hela／MMC细胞对MMC 5.02倍的耐药；3H-TdR实验表明，VER或SDZ PSC833与MMC联用可增加MMC对宫颈癌细胞DNA合成的抑制，且SDZ PSC833作用强于VER，光镜和电镜下形态学观察，联合用药组细胞呈明显退行性变。结论无毒剂量的SDZ PSC833和VER体外能基本逆转Hela／MMC细胞对MMC的耐药性，且SDZ PSC833作用强于VER。SDZ PSC833作为耐药修饰剂可望用于宫颈癌化疗，其临床应用前景优于VER。
목적본연구지재탐토SDZ PSC833화유랍파미(verapamil,VER)대사렬매소(MMC)체외증효작용。방법이인궁경암Hela세포화내약아계Hela／MMC세포위재료，관찰료SDZ PSC833화VER대MMC체외증효작용。결과무독제량적SDZ PSC833화VER(1～3mg/L)가현저증가MMC적세포독작용차가기본극복Hela／MMC세포대MMC 5.02배적내약；3H-TdR실험표명，VER혹SDZ PSC833여MMC련용가증가MMC대궁경암세포DNA합성적억제，차SDZ PSC833작용강우VER，광경화전경하형태학관찰，연합용약조세포정명현퇴행성변。결론무독제량적SDZ PSC833화VER체외능기본역전Hela／MMC세포대MMC적내약성，차SDZ PSC833작용강우VER。SDZ PSC833작위내약수식제가망용우궁경암화료，기림상응용전경우우VER。
Objective To determine the reversion of mitomycin(MMC) resistance by SDZ PSC833 and verapamil (VER) in human cervical cancer in vitro. Methods The reversion of mitomycin resistance by SDZ PSC833 or VER was detected for human cervical cancer cell ( Hela ) and its resistant subline Hela/MMC in vitro.. Results Both nontoxic doses of SDZ PSC833 and VER (1～3mg/L) might enhance the cytotoxicity of MMC in Hela and Hela/MMC and could result in almost complete or partial reversion of MMC -resistance of Hela/MMC. 3H -TdR incorporation test indicated that SDZ PSC833 or VER enhanced the inhibition of DNA synthesis in Hela and Hela/MMC cell. Moreover, the effect of SDZ PSC833 on reversing drug resistance was better than VER in vitro. Conclusions SDZ PSC833 and VER can overcome mitomycin resistance of Hela/MMC in vitro. SDZ PSC833 will be a better candidate for reversing multidrug resistance than verapamil in clinic.